Ibrutinib in association with venetoclax for the treatment of mantle-cell lymphoma: a multicenter case series.
Mantle-cell lymphoma
ibrutinib
venetoclax
Journal
American journal of blood research
ISSN: 2160-1992
Titre abrégé: Am J Blood Res
Pays: United States
ID NLM: 101569577
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
10
2020
accepted:
10
12
2020
entrez:
25
1
2021
pubmed:
26
1
2021
medline:
26
1
2021
Statut:
epublish
Résumé
Mantle-cell lymphoma (MCL) with relapsed/refractory (R/R) disease after intensive chemotherapy have few effective treatment options. Ibrutinib showed a promising median progression-free survival (PFS) with manageable toxicity. The BCL2 inhibitor venetoclax showed encouraging results in R/R MCL patients and preclinical models suggest a potential synergistic effect of dual BTK and BCL2 inhibition. Ibrutinib in association with venetoclax was successfully investigated in a phase II trial. We have retrospectively analyzed 4 patients with R/R MCL receiving daily oral ibrutinib in association with venetoclax. All patients received oral ibrutinib 560 mg per day as monotherapy and subsequently added venetoclax with an initial dose of 50 mg per day, with weekly rump-up until a full dose of 400 mg per day until disease progression. All patients achieved a response, the CR rate was 50%. The aim was to perform an allogeneic SCT (allo-SCT). One patient experienced an early relapse and died because of PD. Allo-SCT was successfully performed in the other 3 patients; ibrutinib and venetoclax were discontinued before allo-SCT. One patient died because of transplant-related complications, while the other 2 cases are alive and in CR. No tumor lysis syndrome occurred. Ibrutinib plus venetoclax represents a promising and feasible treatment option for R/R MCL patients outside clinical trials.
Types de publication
Case Reports
Langues
eng
Pagination
355-359Informations de copyright
AJBR Copyright © 2020.
Déclaration de conflit d'intérêts
None.
Références
N Engl J Med. 2019 May 30;380(22):2095-2103
pubmed: 31141631
Br J Haematol. 2019 May;185(4):656-669
pubmed: 30768675
Am J Hematol. 2020 Jun;95(6):623-629
pubmed: 32239765
J Clin Oncol. 2019 Oct 20;37(30):2722-2729
pubmed: 31295041
J Clin Oncol. 2017 Mar 10;35(8):826-833
pubmed: 28095146
J Clin Oncol. 2018 Oct 25;:JCO1800359
pubmed: 30359156
Blood. 2018 Dec 27;132(26):2722-2729
pubmed: 30385481
N Engl J Med. 2018 Mar 29;378(13):1211-1223
pubmed: 29590547
N Engl J Med. 2013 Aug 8;369(6):507-16
pubmed: 23782157
Nat Med. 2019 Jan;25(1):119-129
pubmed: 30455436
Br J Haematol. 2017 Nov;179(3):430-438
pubmed: 28832957
Haematologica. 2019 May;104(5):e211-e214
pubmed: 30442728
Br J Haematol. 2015 Mar;168(5):765-8
pubmed: 25284608
Ann Oncol. 2017 Jul 1;28(suppl_4):iv62-iv71
pubmed: 28881919